STRO · Categories · Earnings
STRO - Earnings announcements
Sutro Biopharma Inc. (STRO) earnings announcements - real-time wire coverage filtered to Earnings only.
Recent Earnings for STRO
- Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million, with cash runway expected into at least Q4 2026, excluding anticipated milestones from existing collaborations – – Conference call today at 2:00 p.m. PT / 5:00 p.m. ET – SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial resu
- Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs for wholly-owned programs expected in the next 3 years, beginning with novel Tissue Factor ADC, STRO-004, planned for 2H 2025 – – Jane Chung, President and COO, to succeed Bill Newell as CEO and Board Director – – Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million, with cash runway expected into at least Q4 2026, excluding anticipated milestones from existing collaborations – – Conference call today at 2:00 p.m. PT/ 5:00 p.m. ET – SOUTH SAN FRANCISCO, Calif
- Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer- Conference call and webcast to be held on Monday, January 9, 2023 at 1:30 pm PT, or 4:30 pm ET - SOUTH SAN FRANCISCO, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it will host a conference call and webcast to present data from its Phase 1 dose-expansion trial and a registrational path forward for STRO-002, an ADC being developed for the treatment of advanced ovarian cancer. In addition to members of the Sutro management team, the call will feature Dr. R. Wendel Naumann, Investigator in the STRO-002-GM1 stud